Researchers at the University of Hong Kong pioneered a dual immunotherapy combining PD-1 inhibitor nivolumab and CTLA-4 blocker ipilimumab to treat advanced hepatocellular carcinoma. This synergistic approach enhances immune system engagement against tumors, improving patient survival markedly compared to historical standards. The therapy has received global regulatory approval, representing a significant advance in liver cancer care amid its high mortality rate. This dual-checkpoint blockade strategy leverages complementary pathways to counteract tumor immune evasion and is poised to become a new first-line standard for unresectable liver cancer.